FrancophonIA/ELRC3.0 huggingface dataset:
English: Push needle straight onto medicine cartridge.
Maltese: Imbotta l-labra dritta fl-iskartoċċ talmediċina.
English: Immune System Disorder
Maltese: Disturbi fis-Sistema Immuni Rari:
English: • Put used needles in a sharps container or a hard plastic container with a secure lid. Do not throw needles directly into your household waste.
Maltese: • Tirriċiklax il-kontenitur għal oġġetti li jaqtgħu jew bil-ponta wara li jimtela.
English: Also read the package leaflet provided.
Maltese: Jista' jkun li ma jkunux disponibbli l-pakketti taddaqsijiet kollha.
English: In patients treated with teriparatide, lumbar spine, total hip and femoral neck BMD increased between 18 and 24 months by an additional 1.7 %, 0.9 %, and 0.4 %, respectively.
Maltese: Bejn it-18 u l-24 xahar, fil-pazjenti kkurati b'teriparatide, il-BMD talparti lumbari tas-sinsla, tat-total tal-ġenbejn u tal-għonq femorali żdied b'1.7 %, b'0.9 % u b'0.4 %
English: Do not use this medicine after the expiry date which is stated on the carton and pen after EXP.
Maltese: Tużax din il-mediċina wara d-data ta' meta tiskadi li tidher fuq il-kartuna u l-pinna wara
English: Respiratory, thoracic and mediastinal disorders Common: Dyspnoea
Maltese: Disturbi tad-demm u tas-sistema limfatika Komuni: Anemija
English: • pain in the muscles and pain in the joints.
Maltese: • uġigħ fil-muskoli u uġigħ fil-ġogi.
English: • Do not store the FORSTEO with a needle attached as this may cause air bubbles to form in the cartridge.
Maltese: • Qabel ma tarmi l-apparat FORSTEO, kun ċert li neħħejt il-labra tal-pinna.
English: Troubleshooting
Maltese: Manifattur
English: • Store the FORSTEO with the white cap on.
Maltese: • Aħżen il-FORSTEO bil-kappa bajda.
English: Pull out black injection button until it stops.
Maltese: TINJETTAX injezzjoni oħra dak in-nhar.
English: Do not share your pen or your needles as this may risk transmission of infectious agents.
Maltese: Taqsamx il-pinna jew il-labar tiegħek ma' oħrajn għax jista' jkun hemm ir-riskju ta' tixrid ta' sustanzi infettivi.
English: Disposal of Pen Needles and Device Disposal of Pen Needles and FORSTEO Device
Maltese: Disturbi fil-kliewi u fis-sistema urinarja
English: Put large needle cover on needle.
Maltese: Iġbed u aqla' lgħatu tal-labra lkbir u erfgħu.
English: FORSTEO is available in pack sizes of 1 or 3 pens.
Maltese: FORSTEO huwa disponibbli f'pakketti ta' pinna waħda jew ta' 3 pinen.
English: In an open-label study, 503 postmenopausal women with severe osteoporosis and a fragility fracture within the previous 3 years (83 % had received previous osteoporosis therapy) were treated with FORSTEO for up to 24 months.
Maltese: F'studju open-label, 503 nisa wara l-menopawża b'osteoporożi severa u li kellhom ksur ta' fraġilità flaħħar 3 snin (83 % kienu diġà rċevew kura għall-osteoporożi) ġew ikkurati b'FORSTEO għal 24
English: Transient events reported have included nausea, weakness/lethargy and hypotension.
Maltese: L-avvenimenti tranżitorji rrapportati kienu jinkludi tqalligħ, debbulizza/letarġija u pressjoni baxxa.
English: The most common side effects are pain in limb (frequency is very common, may affect more than 1 in 10 people) and feeling sick, headache and dizziness (frequency is common).
Maltese: L-aktar effetti sekondarji komuni huma l-uġigħ fid-dirgħajn u fir-riġlejn (il-frekwenza hija komuni ħafna, tista' tolqot aktar minn persuna 1 minn kull 10) u tħossok ma tiflaħx, uġigħ ta' ras u sturdament (il-frekwenza hija komuni).
English: Small needle protector
Maltese: Tindif u Ħażna
English: • Metabolic bone diseases (including hyperparathyroidism and Paget's disease of the bone) other than primary osteoporosis or glucorticoid-induced osteoporosis.
Maltese: minbarra l-osteoporożi primarja jew l-osteoporożi kkawżata mit-teħid tal-glukokortikojdi.
English: Post-treatment management: Following treatment with FORSTEO, 1262 postmenopausal women from the pivotal trial enrolled in a post-treatment follow-up study.
Maltese: Wara l-kura b' FORSTEO, 1292 mara wara l-menopawża, mill-prova pivotali daħlu f' studju ta' wara l-kura.
English: At baseline, ninety percent of the patients had one or more vertebral fractures, and on average, vertebral BMD was 0.82 g/cm2 (equivalent to a T-score = - 2.6).
Maltese: Fil-linja bażi disgħin fil-mija tal-pazjenti kellhom ksur vertebrali waħdani jew aktar. u bħala medja l-BMD vertebrali kien ta' 0.82 g/cm² (ekwivalenti għal T-score = - 2.6 )
English: 100 mg Film-coated tablet Oral use
Maltese: 100 mg Pillola miksija b'rita Użu orali
English: Film-coated tablet Oral use
Maltese: Pillola miksija b'rita Użu orali
English: (See section 6.6.)
Maltese: (Ara sezzjoni 6.6.)
English: 23 April 2007
Maltese: 23 ta' April 2007
English: 23 April 1997
Maltese: 23 ta' April 1997
English: Gilead Sciences Limited IDA Business & Technology Park Carrigtohill Co. Cork Ireland
Maltese: Gilead Sciences Limited IDA Business & Technology Park Carrigtohill Co. Cork L-Irlanda
English: 6.2 Incompatibilities
Maltese: .2 Inkompatibiltajiet
English: Mutagenicity and reproductive toxicology
Maltese: Mutaġeniċita u tossikoloġija riproduttiva
English: The formulation is adjusted to pH 7.4.
Maltese: Il-formulazzjoni hija aġġustata għal pH 7.4.
English: Maintenance treatment.
Maltese: Trattament ta' manteniment.
English: 1 vial 375 mg/5 ml
Maltese: 1 kunjett 375 mg/5 ml
English: • The potential for interactions between Vistide and anti-HIV protease inhibitors has not been studied.
Maltese: • Il-potenzjal ta' interazzjonijiet bejn Vistide u inibituri protease kontra l-HIV ma ġiex studjat.
English: Cidofovir is active in vitro against HCMV, a member of the herpesviridae family.
Maltese: Cidofovir huwa attiv in vitro kontra l-HCMV, li jifforma parti mil-familja herpesviridae.
English: • aminoglycosides, pentamidine or vancomycin (for bacterial infections)
Maltese: • aminoglycosides, pentamidine jew vancomycin (għal infezzjonijiet batterjali)
English: Probenecid is known to increase the exposure of many substances (e.g., paracetamol, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicyclic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
Maltese: Huwa fatt magħruf li probenecid iżid l-espożizzjoni ta' ħafna sustanzi (eż., paracetamol, acyclovir, aġenti li jinibixxu angiotensin-converting enzyme, aminosalicylic acid, barbiturati, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, aġenti mhux sterojdi għal kontra linfjammazzjoni, theophylline, u zidovudine).
English: Maintenance treatment
Maltese: Trattament ta' manteniment
English: Hypersensitivity reactions, with dermatitis, pruritus, urticaria and, rarely, anaphylaxis, and Stevens-Johnson syndrome have occurred.
Maltese: Reazzjonijiet ta' sensittivita' eċċessiva ġraw, b'dermatite, ħakk, urtikarja u rarament anafilassi, u sindromi Stevens-Johnson.
English: Renal insufficiency [creatinine clearance ≤ 55 ml/min or ≥ 2+ proteinuria (≥ 100 mg/dl)] is a contraindication for the use of Vistide (see sections 4.3 and 4.4).
Maltese: Insuffiċjenza fil-funzjoni tal-kliewi [clearance tal-krejatinina ≤ 55 ml/min jew ≥ 2 + proteini fl-awrina (≥ 100 mg/dl)] hija kontraindikata għal użu ta' Vistide (ara sezzjoni 4.3 u sezzjoni 4.4).
English: Pharmacotherapeutic group: Antivirals for systemic use, nucleosides and nucleotides excluding reverse transcriptase inhibitors, ATC code: J05AB12
Maltese: Aġenti antivirali għall-użu sistemiku, nukleosidi u nukleotidi li jeskludu reverse transcriptase inhibitors, kodiċi ATC:
English: In vitro protein binding
Maltese: Irbit mal-proteini in vitro
English: Sodium hydroxide Hydrochloric acid Water for injections
Maltese: Sodium hydroxide Hydrochloric acid Ilma għall-injezzjonijiet
English: Breast-feeding:
Maltese: Insuffiċjenza tal-fwied:
English: Ocular events
Maltese: Episodji okulari
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/037/001
Maltese: FIS-SUQ EU/1/97/037/001
English: The fraction of the dose extracted during haemodialysis is 51.9 ± 11.0%.
Maltese: Ilfrazzjoni tad-doża li titneħħa permezz tad-dijaliżi tad-demm hija 51.9 ± 11.0%.
English: Vistide is supplied as a sterile concentrate for solution for infusion in clear, glass vials containing 375 mg of the active ingredient, anhydrous cidofovir, formulated in 5 ml water for injections at a concentration of 75 mg/ml.
Maltese: Vistide jiġi bħala konċentrat sterili għal soluzzjoni għall-infużjoni ġo kunjetti tal-ħġieġ trasparenti li fihom 375 mg tas-sustanza attiva, anhydrous cidofovir, f'5 ml ifformulata f'ilma għall-injezzjonijiet f'konċentrazzjoni ta' 75 mg/ml.
English: • Probenecid may interact with other medicines commonly used in the treatment of AIDS and AIDS-related illnesses, such as zidovudine (AZT).
Maltese: • Probenecid jista' jinteraġixxi ma' mediċini oħra li ta' spiss jintużaw fit-trattament tal-AIDS u mard ieħor li għandu x'jaqsam ma' l-AIDS, bħal zidovudine (AZT).
English: There have been reports of leukopenia, hepatic necrosis, nephrotic syndrome, and aplastic anaemia.
Maltese: Kien hemm rapporti ta' lewkopenja, nekrożi tal-fwied, sindromi nefrotika u anemija aplastika.
English: The active substance of Vistide 75 mg/ml is cidofovir.
Maltese: Is-sustanza attiva ta' Vistide 75 mg/ml hija cidofovir.
English: The median times to retinitis progression in the two efficacy studies (GS-93-106 and GS-93-105), were 120 days and not reached for the treatment arms vs. 22 days and 21 days for the untreated (deferred treatment) arms, respectively.
Maltese: Iż-żmien medjan sa ma kien hemm progressjoni għal retinite fiż-żewġ studji ta' l-effikaċja (l-istudji GS-93-106 u GS-93-105) kien ta' 120 jum u ma kienx milħuq f'dawk li ħadu t-trattament vs. 22 jum u 21 jum għal dawk li ma ħadux trattament (trattament diferit), rispettivament.
English: Possible side effects of taking probenecid
Maltese: Effetti sekondarji possibbli meta jittieħed probenecid
English: For storage conditions of the diluted medicinal product, see section 6.3.
Maltese: Għall-kundizzjonijiet ta' ħażna tal-prodott mediċinali dilwit, ara sezzjoni 6.3. 6.5
English: The mean values of total serum clearance, volume of distribution at steady-state and terminal elimination halflife were 138 (± 36) ml/h/kg, 388 (± 125) ml/kg and 2.2 (± 0.5) h, respectively.
Maltese: Ilvaluri medji tat-tneħħija totali mis-serum, tal-volum tad-distribuzzjoni meta jkun intlaħaq stat fiss u lhalf-life fil-fażi terminali ta' l-eliminazzjoni kienu 138 (± 36) ml/siegħa/kg, 388 (± 125) ml/kg u 2.2 (± 0.5) siegħa, rispettivament.
English: Cidofovir is a cytidine analogue with in vitro and in vivo activity against human cytomegalovirus (HCMV).
Maltese: Cidofovir huwa analogu ta' cytidine b'effett kontra human cytomegalovirus (HCMV) kemm in vitro kif ukoll in vivo.
English: Common side effects possibly related to probenecid (These can affect 1 to 10 users in 100)
Maltese: Effetti sekondarji komuni possibilment relatati ma' probenecid (Dawn jistgħu jaffettwaw minn 1 sa 10 utenti minn kull 100)
English: Each ml contains 75 mg cidofovir anhydrous.
Maltese: Kull ml fih 75 mg cidofovir anhydrous.
English: The in vitro sensitivity to cidofovir is shown in the following table:
Maltese: Is-sensittività in vitro għal cidofovir tidher fit-tabella li jmiss:
English: • adefovir (for HBV infection)
Maltese: • adefovir (għal infezzjoni bl-HBV)
English: Iritis, uveitis, hypotony of the eye (see section 4.4)
Maltese: Iritis, uveitis, tnaqqis fil-pressjoni ta' ġolgħajn (ara sezzjoni 4.4)
English: Excipients:
Maltese: Ġenerali:
English: Vistide must be diluted in 100 millilitres 0.9% (normal) saline prior to administration.
Maltese: Vistide għandu jiġi dilwit f'100 millilitru ta' salina (normali) 0.9 % qabel ma jingħata.
English: The preparation of Vistide diluted solution should be done in a laminar flow biological safety cabinet.
Maltese: Ilpreparazzjoni tas-soluzzjoni dilwita ta' Vistide għandha ssir ġo cabinet tas-sigurtà bijoloġiku tat-tip laminar flow.
English: An increase in formation of micronucleated polychromatic erythrocytes was observed in vivo in mice receiving a high, toxic intraperitoneal dose of cidofovir (≥ 2,000 mg/kg).
Maltese: Kien hemm żieda fl-ammont ta' eritroċiti polikromatiċi mikronuklejati, in vivo, fi ġrieden li ngħataw doża għolja u tossika ta' cidofovir ġol-peritonew (≥ 2000 mg/kg).
English: Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849
Maltese: Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849
English: • Vistide is not used for the treatment of HIV infection.
Maltese: • Vistide ma jintużax għat-trattament ta' infezzjoni HIV.
English: Biochemical data support selective inhibition of HSV-1, HSV-2 and HCMV DNA polymerases by cidofovir diphosphate, the active intracellular metabolite of cidofovir.
Maltese: Tagħrif biokimiku jindika li dan jiġri permezz ta' inibizzjoni selettiva ta' polymerases tad-DNA f'HSV-1, HSV-2 u HCMV permezz ta' cidofovir diphosphate, li hija s-sustanza ffurmata fil-metaboliżmu ta' cidofovir ġewwa ċ-ċelluli.
English: Prolonged antiviral effects of cidofovir are related to the half-lives of its metabolites; cidofovir diphosphate persists inside cells with a half-life of 17-65 hours and a cidofovir phosphate-choline adduct has a half-life of 87 hours.
Maltese: Effetti fit-tul ta' cidofovir kontra l-virus huma relatati mal-half-lives tas-sustanzi li jiġu ffurmati b'riżultat tal-metaboliżmu tiegħu; cidofovir diphosphate jippersisti ġoċ-ċelluli, b'half-life ta' 17-65 siegħa filwaqt li is-sustanza magħquda ta' phosphate-choline għandha half-life ta' 87 siegħa.
English: In study GS-93-107 conducted in patients who had relapsed after treatment with other agents, the median time to retinitis progression was 115 days.
Maltese: Fl-istudju GS-93-107 li sar fuq pazjenti li rkadew wara trattament b'aġenti oħrajn, iż-żmien medjan sa ma kien hemm progressjoni għal retinite kien ta' 115-il jum.
English: Therapy must be accompanied by administration of oral probenecid and adequate intravenous saline prehydration (see section 6.6 for information on obtaining probenecid) with each cidofovir dose.
Maltese: It-terapija għandha tingħata flimkien ma' probenecid mill-ħalq u pre-idrazzjoni ġol-vina b'saline adegwata (ara sezzjoni 6.6 għal informazzjoni kif takkwista probenecid) ma' kull doża ta' cidofovir.
English: Nephrotoxicity
Maltese: Newtropenja
English: 1 g probenecid
Maltese: 1 g ta' probenecid
English: Each vial contains 375 mg/5 ml cidofovir anhydrous.
Maltese: Kull kunjett fih 375 mg/5 ml cidofovir anhydrous.
English: Normal saline is given to lower the risk of kidney damage.
Maltese: Is-salina normali tingħata biex jitnaqqas ir-riskju ta' ħsara fil-kliewi.
English: 4 g probenecid
Maltese: 4 g ta' probenecid
English: What is CMV retinitis?
Maltese: X'inhi r-retinite kkawżata mis-CMV?
English: There is a risk that concomitant treatment of Vistide with products containing tenofovir disoproxil fumarate may give rise to a pharmacodynamic interaction and increase the risk of Fanconi syndrome (see section 4.4).
Maltese: Hemm riskju li l-użu fl-istess ħin tal-kura ta' Vistide ma' prodotti li fihom tenofovir disoproxil fumarate jista' jikkawża interazzjoni farmakodinamika u jżid ir-riskju tas-sindrome ta' Fanconi (ara sezzjoni 4.4).
English: Marketing Authorisation Holder Gilead Sciences International Limited Cambridge
Maltese: Id-detentur ta' l-Awtorizzazzjoni għat-tqegħid fis-suq Gilead Sciences International Limited Cambridge
English: 2 g probenecid
Maltese: 2 g ta' probenecid
English: Probenecid increases the AUC of zidovudine.
Maltese: Probenecid iżid l-AUC ta' zidovudine.
English: Each pack contains one 5 ml vial.
Maltese: Kull pakkett fih kunjett wieħed ta' 5 ml.
English: The formulation is pH-adjusted with sodium hydroxide (and hydrochloric acid if needed) and contains no preservatives.
Maltese: Il-formulazzjoni għandha l-pH tagħha aġġustat b'sodium hydroxide (u jekk ikun hemm bżonn b'hydrochloric acid) u ma għandha ebda preservattivi.
English: In addition probenecid may also cause other adverse reactions including anorexia, gingival pain, flushing, alopecia, dizziness, anaemia, and pollakiuria.
Maltese: Barra minn dawn, probenecid jista' wkoll jikkawża reazzjonijiet avversi oħra, inklużi anoressija, uġiegħ fil-ħanek, fwawar, alopeċja, sturdament, anemija u pollakijurja.
English: Vistide should not be administered concurrently with medicinal products containing tenofovir disoproxil fumarate due to the risk of Fanconi syndrome (see section 4.5).
Maltese: Vistide m'għandux jingħata fl-istess ħin ma' prodotti mediċinali li fihom tenofovir disoproxil fumarate minħabba r-riskju tas-sindrome ta' Fanconi (ara sezzjoni 4.5).
English: Cidofovir enters cells by fluid-phase endocytosis and is phosphorylated to cidofovir monophosphate and subsequently to cidofovir diphosphate.
Maltese: Cidofovir jidħol fiċ-ċelluli permezz ta' endoċitożi f'fażi fluwida u jiġi fosforilat għal cidofovir monophosphate u wara għal cidofovir diphosphate.
English: These medicines must be stopped at least 7 days before taking Vistide.
Maltese: Dawn il-mediċini għandhom jitwaqqfu mill-anqas 7 ijiem qabel ma tieħu Vistide.
English: At the end of a one-hour infusion of cidofovir 5 mg/kg administered with concomitant oral probenecid, the mean (± SD) serum concentration of cidofovir was 19.6 (± 7.18) µg/ml.
Maltese: Fi tmiem infużjoni fuq medda ta' siegħa ta' cidofovir 5 mg/kg u li magħha ngħata wkoll probenecid mill-ħalq, il-konċentrazzjoni medja (± SD) ta' cidofovir fis-serum kienet ta'19.6 (± 7.18) µg/ml.
English: The safety of cidofovir has not been evaluated in patients receiving other known potentially nephrotoxic agents (e.g. tenofovir, aminoglycosides, amphotericin B, foscarnet, intravenous pentamidine, adefovir and vancomycin).
Maltese: Is-sigurta' ta' cidofovir f'pazjenti li jkunu jieħdu xi mediċini oħrajn li huma magħrufin li jistgħu jagħmlu ħsara għall-kliewi (e.g. tenofovir, aminoglycosides, amphotericin B, foscarnet, pentamidine ġol-vina, adefovir u vancomycin)għada ma gietx evalwata.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Maltese: Informazzjoni dettaljata dwar din il-mediċina tinsab fuq is-sit elettroniku ta' l-Aġenzija Ewropea dwar il-Mediċini http://www.ema.europa.eu/.
English: Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) or not known (cannot be estimated from the available data).
Maltese: < 1/10), mhux komuni (≥ 1/1,000 sa < 1/100) jew mhux magħruf (ma tistax tittieħed stima mid-data disponibbli).
English: • nausea, vomiting, rash and fever.
Maltese: • dardir, rimettar, raxx u deni.
English: Each vial contains 375 mg/5 ml cidofovir anhydrous as the active substance.
Maltese: Kull kunjett fih 375 mg/5 ml cidofovir anhydrous bħala sustanza attiva.
English: Each vial contains approximately 2.5 mmol (or 57 mg) sodium per vial (5 ml) as a constituent of the excipients.
Maltese: Kull kunjett fih bejn wieħed u ieħor 2.5 mmol (jew 57 mg) sodju f'kull kunjett (5 ml) bħala kostitwent tas-sustanzi mhux attivi.
English: One patient received a single dose of 16.4 mg/kg and the other patient received a single dose of 17.3 mg/kg.
Maltese: Wieħed millpazjenti kien ingħata doża waħda ta' 16.4 mg/kg, u l-ieħor kien ingħata doża waħda ta' 17.3 mg/kg.
English: Men should be advised to practice barrier contraceptive methods during and for 3 months after treatment with cidofovir (see sections 4.6 and 5.3).
Maltese: L-irġiel għandhom jingħataw parir biex jużaw metodi ta' kontraċezzjoni barriera waqt u sa 3 xhur wara t-trattament b'cidofovir (ara sezzjonijiet 4.6 u 5.3).
English: Cidofovir diphosphate inhibits these viral polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerases alpha, beta, and gamma.
Maltese: Cidofovir diphosphate jinibixxi dawn il-polymerases tal-virus anki f'konċentrazzjonijiet li huma minn 8 sa 600 darba aktar baxxi minn dawk li hemm bżonn biex jinibixxi d-DNA polymerases alpha, beta u gamma fiċ-ċelluli tal-ġisem tal-bniedem.
English: These include: • tenofovir containing medicines, used to treat HIV-1 infection and/or chronic hepatitis B
Maltese: • mediċini li fihom tenofovir, li jintużaw għal kura ta' infezzjoni bl-HIV-1 u/jew infezzjoni
English: The no-observable-effect doses for embryotoxicity were 0.5 mg/kg/day in rats and 0.25 mg/kg/day in rabbits.
Maltese: Id-dożi li bihom ma ġiex osservat effett tossiku fuq lembriju kienu ta' 0.5 mg/kg/kuljum fil-firien u 0.25 mg/kg/kuljum fil-fniek.
English: In patients with normal renal function, 80 to 100% of the intravenous dose was recovered in the urine over 24 hours as unchanged cidofovir.
Maltese: F'pazjenti b'funzjoni normali tal-kliewi, 80-100 % tad-doża li ngħatat fil-vina reġgħet ġiet irkuprata fl-awrina bħala cidofovir mhux mibdul, fuq medda ta' 24 siegħa.
English: Vistide 75 mg/ml concentrate for solution for infusion Cidofovir
Maltese: Vistide 75 mg/ml konċentrat għal soluzzjoni għall-infużjoni Cidofovir
English: Evidence for a nephroprotective effect for probenecid was shown in a 52-week study conducted in cynomolgus monkeys administered cidofovir 2.5 mg/kg once weekly intravenously with 1 g of probenecid given orally.
Maltese: Fi studju mifrux fuq 52 ġimgħa u li sar fuq xadini tal-ġenus cynomolgus, fejn dawn ingħataw cidofovir 2.5 mg/kg ġol-vina darba fil-ġimgħa flimkien ma' 1g probenecid li ngħata mill-ħalq, ħarġet evidenza li turi li probenecid fil-fatt għandu l-effett li jipproteġi l-kliewi.
English: In vivo activity against HCMV was confirmed with controlled clinical studies of cidofovir for the treatment of CMV retinitis in patients with AIDS, which demonstrated statistically significant delays in time to CMV retinitis progression for patients on cidofovir when compared to control patients.
Maltese: L-attività in vivo ta' kontra l-HCMV fil-bniedem, ġiet konfermata permezz ta' studji kliniċi kkontrollati li fihom cidofovir intuża għat-trattament ta' retinite kkawżata mis-CMV f'pazjenti blAIDS, u fejn intwera li f'pazjenti li kienu fuq cidofovir kellhom dewmien statistikament sinifikanti sa ma żviluppaw retinite kkawżżata mis-CMV, meta mqabbla ma' pazjenti tal-kontroll.
English: • Kidney damage is the major side effect of Vistide treatment.
Maltese: Dawn l-effetti sekondarji ġeneralment imorru meta jitwaqqaf it-trattament b'Vistide.
English: Neutropenia
Maltese: Pankreatite
English: The chemical stability of Vistide mixed in saline solution has been demonstrated in glass bottles, in infusion bags composed of either polyvinyl chloride (PVC) composition or ethylene/propylene copolymer, and in PVC based vented IV administration sets.
Maltese: L-istabbiltà kimika ta' Vistide meta dan kien imħallat mas-salina kienet intweriet fi fliexken tal-ħġieġ, f'boroż ta' l-infużjonijiet magħmula minn polyvinyl chloride (PVC), jew ethylene/propylene copolymer, u anki f'settijiet ta' l-infużjoni ġol-vina b'vent, magħmulin bil-bażi tal-PVC.
English: Vistide is indicated for the treatment of CMV retinitis in adults with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction.
Maltese: Vistide hu indikat għat-trattament ta' retinite b'CMV fl-adulti li għandhom is-sindromu ta' limmunodefiċjenza akkwiżita (AIDS) u mingħajr tħassir fil-funzjoni tal-kliewi.
English: Chemical and physical in-use stability has been demonstrated for up to 24 hours at 2 - 8ºC when dilution is performed under controlled and validated aseptic conditions.
Maltese: Stabbilta' kimika u fiżika waqt l-użu ġiet murija li hi l-iktar sa 24 siegħa f'temperatura ta' 2 - 8ºC, meta ikun dilwit taħt kundizzjonijiet asettiċi kontrollati u validati.
English: Renal and urinary disorders Very common
Maltese: Disturbi fil-kliewi u fis-sistema urinarja Komuni ħafna